预约演示
AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
临床结果上市批准
AstraZeneca (AZ) and Merck’s – known as MSD outside the US and Canada – Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for a subset of ovarian cancer patients.
AstraZeneca (AZ)n speMerckally recommended for NHS use alongside GenenteLynparzastolaparibcizumab) as a maintenance treaNational Institute for Health and Care Excellence (NICE)ian tube or primary peritoneal cancer, whose diseaseovarian cancer with homologous recombination deficiency (HRD)-positive status.
Eligible patients will also need to be in complete or partial resGenentechfirAvastin (bevacizumab)d chemotherapy.
Ovarian cancer is the sixth most common cancer in the UK, with 7,400 new cases of the disease diagnosed every year.
Ovarian cancer patients with advanced hicancerde ovarian cancer have HRD, when the body is unable to repair breaks in the DNA.
Given as a tablet, Lynparza works by inhibiting the PARP enzyme, which helps cells repair damaged DNA. By blocking this enzyme, PARP inhibitors prevent the DNA of cancer cells from being repaired, preventing them from growing and spreading.
NICE’s final draft Lynparza on the treatment was supported by positive results from the late-stage PAOLA-1 trial, in which the cPARP inhibitorsPARPnation reduced the risk of deatcancer7% in patients with HRD-positive advanced ovarian cancer.
Tom Keith-Roach, president, AZ UK, said: “We are delighted with this recommendation for women with advanced HRD-positive ovarian cancer.HRD-positive advanced ovarian cancer
“[Lynparza] was discovered aAZ UKveloped in England, and it is important that UK patients can routiadvanced HRD-positive ovarian canceres.”
LyLynparzaas been available on the NHS in England and Wales for patients with advanced ovarian cancer, and inherited BRCA1 or BRCA2 mutations who have stopped responding to treatment since January 2020.
Lynparza was also recommended by NICE in April this year for adults with HER2-advanced ovarian cancerly breast cancerBRCA1haveBRCA2rited faults in their BRCA1 or BRCA2 genes after surgery and chemotherapy, as well as for adults with previously treated hormone-relapsed metastatic prostate cancer who have the same BRCA mutations.
Keith-Roach said at the time: “This is a hard-won and extremely importantHER2-negative, high-risk early breast cancer follows on from the successful NICEBRCA1th tBRCA2logy assessment process.hormone-relapsed metastatic prostate cancer
"Innovative oncology medicines such as [Lynparza] often show effectiveness across multiple different cancer types and, in these situations, it’s essential that we continue to advance pricing and reimbursement pathways which support rapid and appropriate patient access.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。